BIOIMPEDANCE DERIVED SARCOPENIA AND PHASE-ANGLE PREDICT TOXICITY AND SURVIVAL AFTER CART CELL THERAPY (SIE 2026) - Oct 6, 2026 - Abstract #DP163; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "CAR-T prod- ucts were axi-cel (n=25), tisa-cel (n=9), and brexu-cel (n=6). Sarcopenia predicts inferior PFS, while dy- namic PhA changes act as an early biomarker of CRS and ICANS. Prospective validation is warranted."
CAR T-Cell Therapy • IO biomarker • Acute Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Movement Disorders • Sarcopenia
|
|
M. Farina1; G. Brambilla1,2; E. Morello1; G. Magliano1; S. Zanon1; V. Radici1; R. De Domenico1; L. Donati1; P. Clementi1; F. Bonati1; F. Re1,3; B. Xhahysa1,3; A. Leoni1,3; S. Bernardi1,3; M. Andreoli2; D. Avenoso1; M. Malagola1; D. Russo1
|